Pulmonary cryptococcosis in the setting of tofacitinib therapy for psoriasis

Academic Article

Abstract

  • Copyright © 2015 Journal of Drugs in Dermatology. Tofacitinib is a novel drug that inhibits the JAK-STAT signaling pathway. It has been approved for the treatment of psoriatic arthritis and it is under investigation for the treatment of psoriasis and other inflammatory disorders. We report a case of pulmonary cryptococcosis in an otherwise immunocompetent patient taking tofacitinib for psoriasis. We hypothesized that tofacitinib contributed to this infection through inhibition of cytokines required for differentiation of T cells and suppression of macrophage activation. As dermatologists begin to use this drug they should be aware of the potential for cryptococcocal infection, because delay of diagnosis may increase the risk of a life-threatening outcome.
  • Author List

  • Seminario-Vidal L; Cantrell W; Elewski BE
  • Start Page

  • 901
  • End Page

  • 902
  • Volume

  • 14
  • Issue

  • 8